. Author manuscript; available in PMC: 2016 Jul 22.

Published in final edited form as: Med Oncol. 2016 Jan 9;33(2):13. doi: 10.1007/s12032-015-0728-2

Table 3.

Median Treatment Failure-Free Survival for Patients Treated with nab-Paclitaxel

Patient Characteristic	Number of Patients	Median Time to Treatment Failure (in Months)	p Value (by log-rank test)
All Patient	31	3.5 (95% CI = 1.3 – 5.3)
Prior Taxane	7	2.2 (95% CI = 0.7 – 4.8)	0.10
No Prior Taxane	24	3.5 (95% CI = 1.3 – 7.9)	0.10
Nab-Paclitaxel as 2^nd Line	13	2.2 (95% CI = 1.3 – 5.3)	0.78
Nab-Paclitaxel beyond 2^nd Line	18	3.6 (95% CI = 1.2 – 7.9)	0.78
Adenocarcinoma	26	3.6 (95% CI = 1.4 – 7.4)	0.03
Non-Adenocarcinoma (Including Mixed Adenocarcinoma and Squamous Cell Carcinoma)	5	1.3 (95% CI = 0.7 – not estimated)	0.03